MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
1.610
+0.040
+2.55%
Closed 19:55 03/27 EDT
OPEN
1.600
PREV CLOSE
1.570
HIGH
1.680
LOW
1.561
VOLUME
593.41K
TURNOVER
0
52 WEEK HIGH
19.04
52 WEEK LOW
1.450
MARKET CAP
78.69M
P/E (TTM)
-0.7421
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CABA last week (0317-0321)?
Weekly Report · 4d ago
Weekly Report: what happened at CABA last week (0310-0314)?
Weekly Report · 03/17 09:01
Weekly Report: what happened at CABA last week (0303-0307)?
Weekly Report · 03/10 09:01
Weekly Report: what happened at CABA last week (0224-0228)?
Weekly Report · 03/03 09:01
Weekly Report: what happened at CABA last week (0217-0221)?
Weekly Report · 02/24 09:01
Promising Clinical Advances and Strategic Developments Justify Buy Rating for Cabaletta Bio
TipRanks · 02/18 22:05
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 02/18 18:32
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Benzinga · 02/18 18:22
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.